Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
Completed
Gedeon Richter Ltd.
Phase 2
2007-06-01
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188
monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks
double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility
criteria will be randomized to one of two treatment groups: RGH-188 or placebo
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
Completed
Forest Laboratories
Phase 2
2007-06-01
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188
monotherapy in the treatment of acute mania. This study will be 5 weeks in duration; 3 weeks
double-blind treatment and 2-weeks safety follow-up. All patients meeting the eligibility
criteria will be randomized to one of two treatment groups: RGH-188 or placebo
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Completed
Gedeon Richter Ltd.
Phase 2
2008-06-30
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188)
relative to placebo in adult patients (18-60 years of age) with acute exacerbation of
schizophrenia.
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Completed
Forest Laboratories
Phase 2
2008-06-30
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188)
relative to placebo in adult patients (18-60 years of age) with acute exacerbation of
schizophrenia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
